Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood

Clinical Biochemistry

Volumn 30, Issue 6, 1997, Pages 491-496

  Lein, Michael ^a,b   Nowak, Lars ^a   Jung, Klaus ^a   Koenig, Frank ^a,b   Lichtinghagen, Ralf ^c   Schnorr, Dietmar ^a   Loening, Stefan A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Massachusetts General Hospital ^*

Author keywords

Metalloproteinase 1; Preanalytical factors; Tissue inhibitor of metalloproteinase 1

Indexed keywords

METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANALYTIC METHOD; ARTICLE; BLOOD CHEMISTRY; CANCER INVASION; DATA ANALYSIS; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RELIABILITY;

EID: 0030774552     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(97)00097-0     Document Type: Article

References (27)

1. Twining SS. Regulation of proteolytic activity in tissues. Crit Rev Biochem Mol Biol 1994; 29: 315-83.
2. Crawford HC, Matrisian LM. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1995; 14: 234-45.
3. Anderson IC, Sugarbaker DJ, Ganju RK, et al. Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res 1995; 55: 4120-6.
4. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2: 461-2.
5. Davies B, Miles DW, Happerfield LC, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993; 67: 1126-31.
6. Yamagata S, Yoshii Y, Suh JG, Tanaka R, Shimizu S. Occurrence of an active form of gelatinase in human gastric and colorectal carcinoma tissues. Cancer Lett 1991; 59: 51-5.
7. Nagase H. Matrix metalloproteinases. Contrib Nephrol 1994; 107: 85-93.
8. Zucker S, Mancuso P, DiMassimo B, Lysik RM, Conner C, Wu C-L. Comparison of techniques for measurement of gelatinases/type IV collagenases: enzyme-linked immunoassays versus substrate degradation assays. Clin Exp Metastasis 1994; 12: 13-22.
9. Zucker S, Lysik RM, DiMassimo BI, et al. Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer 1995; 76: 700-8.
10. Kodama S, Iwata K, Iwata H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma. J Immunol Methods 1990; 127: 103-8.
11. Plumpton TA, Clark IA, Plumpton C, Calvin J, Cawston TE. Development of an enzyme-linked immunosorbent assay to measure total TIMP-1 (Free TIMP-1 and TIMP-1 in combination with matrix-metalloproteinases) and measurement of TIMP-1 and CRP in serum. Clin Chim Acta 1995; 240: 137-54.
12. Zucker S, Lysik RM, Gurfinkel M, et al. Immunoassay of type IV collagenase/gelatinase (MMP-2) in human plasma. J Immunol Methods 1992; 148: 189-98.
13. Solberg HE. Approved recommendations (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determinations of reference limits. J Clin Chem Clin Biochem 1987; 25: 645-56.
14. Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993; 36: 372-9.
15. Murawaki Y, Ikuta Y, Nishimura Y, Koda M, Kawasaki H. Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis. J Hepatol 1995; 23: 145-52.
16. Maeda S, Sawai T, Uzuki M, et al. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54: 970-5.
17. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 1994; 70: 506-12.
18. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe-Seyler 1995; 376: 345-55.
19. Garbisa S, Scagliotti G, Masiero L, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992; 52: 4548-9.
20. Garzetti GG, Ciavattini A, Lucarini G, et al. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res 1995; 15: 2799-804.
21. Boyd D. Invasion and metastasis. Cancer Metast Rev 1996; 15: 77-89.
22. Cooper TW, Eisen AZ, Stricklin GP, Welgus HG. Platelet-derived collagenase inhibitor: characterization and subcellular localization. Proc Nat Acad Sci USA 1985; 82: 2779-83.
23. Matsuki H, Fujimoto N, Iwata K, Knäuper V, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 8 (neutrophil collagenase) using monoclonal antibodies. Clin Chim Acta 1996; 244: 129-43.
24. Manicourt DH, Fujimoto N, Obata K, Thonar EJ. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 1995; 38: 1031-9.
25. Okumura Y, Sato H, Seiki M, Kido H. Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. FEBS Letters 1997; 402: 181-4.
26. Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H. Charakterization of tissue inhibitor of metalloproteinases-1 in plasma drom patients with chronic liver diseases. Clin Chim Acta 1996; 254: 77-83.
27. Ishiguro N, Ito T, Obata K, Fujimoto N, Iwata H. Determination of stromelysinn-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol 1996; 23: 1599-604.